NITROUS OXIDE, USP
Clinical safety rating
cautionComprehensive clinical and safety monograph for NITROUS OXIDE, USP (NITROUS OXIDE, USP).
Nitrous oxide is an inhalational anesthetic with analgesic, anxiolytic, and amnestic properties. It acts as a non-competitive NMDA receptor antagonist, inhibits GABA-A receptors, and modulates opioid receptors, leading to altered neurotransmission and dissociation.
| Metabolism | Nitrous oxide is metabolized minimally (approximately 0.004%) via intestinal bacterial reduction to free radicals and nitrogen. Pulmonary excretion unchanged accounts for >99% of elimination. |
| Excretion | Primarily eliminated via lungs as unchanged gas (>99% exhaled); negligible renal (<1%) or biliary/fecal elimination. |
| Half-life | Terminal elimination half-life is 2–6 minutes (context-sensitive); rapid washout due to low blood solubility and high pulmonary elimination. |
| Protein binding | <0.5% (minimally bound; essentially unbound in plasma). |
| Volume of Distribution | 0.5–1.0 L/kg (rapid distribution to vessel-rich tissues; maintains rapid onset and offset). |
| Bioavailability | Inhalation: 100% (administered as gas; absorbed directly across alveolar membrane). |
| Onset of Action | Inhalation: 30–60 seconds (analgesia at 20–50% concentration; anesthesia at 50–70%). |
| Duration of Action | 2–5 minutes after discontinuation; clinical effects dissipate rapidly due to fast pulmonary elimination; full recovery usually within 5–10 minutes. |
| Molecular Weight | 44.013 |
Inhalation: 25-75% nitrous oxide in oxygen for sedation; 50-70% for anesthesia, titrated to effect.
| Dosage form | GAS |
| Renal impairment | No dose adjustment required; nitrous oxide is minimally excreted renally. |
| Liver impairment | No dose adjustment required; metabolism is minimal. |
| Pediatric use | Inhalation: 5-50% nitrous oxide in oxygen, titrated to effect; for anesthesia, up to 70%. |
| Geriatric use | Decrease concentration and titrate slowly due to increased sensitivity; monitor for hypotension and hypoxia. |
| 1st trimester | Limited data; avoid elective use in first trimester. Nitrous oxide is teratogenic in animal studies at high doses, but clinical significance is unclear. Use only if clearly needed. |
| 2nd trimester | May be used for short-term anesthesia if necessary; no known increased risk of malformations from brief exposure. |
| 3rd trimester | Use cautiously; may cause fetal depression or hypoxia with prolonged exposure. Avoid prolonged administration near term. |
Clinical note
Comprehensive clinical and safety monograph for NITROUS OXIDE, USP (NITROUS OXIDE, USP).
| Placental transfer | Rapidly crosses placenta; fetal concentrations reach about 80% of maternal levels within minutes. |
| Breastfeeding | Nitrous oxide is rapidly eliminated via lungs; negligible amounts enter breast milk. No adverse effects on infants reported. Considered compatible with breastfeeding after short-term use. |
| Lactation Rating | L2 (Safer) or 'Safe' |
| Teratogenic Risk | Nitrous oxide is classified as FDA Pregnancy Category C. First trimester: In vitro and animal studies suggest potential teratogenicity at high concentrations; limited human data show no increased risk of major malformations with brief, low-dose exposure. Second/third trimesters: Use is generally considered safe for short durations; prolonged or repeated exposure may reduce uterine blood flow and cause fetal hypoxia. There is no evidence of increased congenital anomalies from routine use in dentistry or surgery. |
| Fetal Monitoring | For pregnant patients, continuous pulse oximetry and capnography are recommended during administration. Monitor fetal heart rate if prolonged exposure (>30 minutes) or if maternal hypoxia is suspected. Assess maternal oxygen saturation and end-tidal nitrous oxide concentrations to minimize risk of hypoxia. |
| Fertility Effects | Occupational exposure to subanesthetic concentrations has been associated with reduced fertility and increased risk of spontaneous abortion in female healthcare workers. However, with proper scavenging systems, no adverse effects on fertility are observed. Single, brief anesthetic exposures do not appear to impair fertility. |
■ FDA Black Box Warning
Nitrous oxide may cause megaloblastic anemia and neurological complications with prolonged use (e.g., >24 hours) due to inactivation of vitamin B12 and folate deficiency. Monitor for signs of B12 deficiency.
| Serious Effects |
PneumothoraxAir embolismDecompression sicknessBowel obstructionPneumocephalusGas embolismHead injury with pneumocephalus or intracranial airSevere bullous emphysemaMiddle ear surgery without tympanostomy tubesInability to maintain airway
| Precautions | Risk of hypoxia due to diffusion hypoxia upon discontinuation; oxygen supplementation required. May cause bone marrow suppression, B12 deficiency neuropathy, and impaired vitamin B12-dependent enzyme activity. Use caution in patients with pre-existing neurological disease, hematologic disorders, or vitamin B12/folate deficiency. Chronic exposure can lead to reproductive toxicity and occupational hazard. |
| Food/Dietary | No specific food interactions. However, patients with vitamin B12 deficiency or those on methotrexate should ensure adequate B12 and folate intake; nitrous oxide can deplete B12 stores. Heavy meals before sedation may increase risk of aspiration and nausea. |
| Clinical Pearls | Nitrous oxide has a rapid onset (30-60 seconds) and offset; monitor for diffusion hypoxia upon discontinuation by administering 100% oxygen for 3-5 minutes. Avoid in patients with pneumothorax, bowel obstruction, middle ear surgery, or intracranial air due to risk of expansion. Use with caution in patients with vitamin B12 deficiency or methylenetetrahydrofolate reductase (MTHFR) mutations due to inactivation of methionine synthase. Nitrous oxide is a potent analgesic but weak anesthetic; always combine with an amnestic agent (e.g., benzodiazepine) for procedural sedation. In pediatric patients, use 30-50% concentration; higher concentrations may cause vomiting or excitement. Check waste gas scavenging systems to prevent occupational exposure. |
| Patient Advice | You may feel lightheaded, euphoric, or have tingling sensations; this is normal and will resolve quickly after stopping the gas. · You will receive oxygen after the procedure to prevent a sudden drop in oxygen levels. · Do not eat a heavy meal for 2-3 hours before sedation to reduce the risk of nausea or vomiting. · Inform your healthcare provider if you have a history of vitamin B12 deficiency, anemia, or lung problems (e.g., pneumothorax). · You should not drive, operate machinery, or make important decisions for 24 hours after sedation. |
Loading safety data…